This is a summary of the European public assessment report (EPAR) for Pergoveris. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pergoveris. For practical information about using Pergoveris, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (LH) and follicle-stimulating-hormone deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.
Therapeutic Area (MeSH)
N/AATC Code
G03GA30
ATC Item
combinations
Pharmacotherapeutic Group
Sex hormones and modulators of the genital system
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Pergoveris
Medicine Name
Pergoveris
Aliases
N/ANo risk management plan link.
